The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 17 07 2021
revised: 20 09 2021
accepted: 17 10 2021
pubmed: 10 11 2021
medline: 16 3 2022
entrez: 9 11 2021
Statut: ppublish

Résumé

In allogeneic haematopoietic stem cell transplant (allo-HSCT) recipients, the inter-relationship between post-transplant cytomegalovirus (CMV) and subsequent invasive fungal infections (IFIs) is conflicting and the association of CMV serostatus with IFIs has not been evaluated. To determine the relationship between CMV infection/serostatus and IFIs in allo-HSCT populations. A systematic literature search was conducted from existence until 11 July 2021 using Medline, Embase and ISI Web of Science databases. Cross-sectional, prospective cohort, retrospective cohort and case-control studies that reported allo-HSCT recipients with CMV and without CMV who developed or did not develop IFIs after CMV infection. Allo-HSCT recipients. Not applicable. A systematic search, screening, data extracting and assessing study quality were independently conducted by two reviewers. The Newcastle-Ottawa scale was used to assess risk of bias. data were analysed using the pooled effect estimates of a random-effects model. A total of 18 and 12 studies were included for systematic review and meta-analysis, respectively. Post-transplant CMV infection significantly increased the risk of IFIs with a pooled hazard ratio (pHR) of 2.58 (1.78, 3.74), I Post-transplant CMV infection and high-risk CMV serostatus increased the risk of IFIs, but low-risk CMV serostatus decreased risk of IFIs among allo-HSCT recipients. Further studies are needed to identify at-risk allo-HSCT recipients as well as to focus on fungal diagnostics and prophylaxis to prevent this fungal-after-viral phenomenon.

Sections du résumé

BACKGROUND BACKGROUND
In allogeneic haematopoietic stem cell transplant (allo-HSCT) recipients, the inter-relationship between post-transplant cytomegalovirus (CMV) and subsequent invasive fungal infections (IFIs) is conflicting and the association of CMV serostatus with IFIs has not been evaluated.
OBJECTIVES OBJECTIVE
To determine the relationship between CMV infection/serostatus and IFIs in allo-HSCT populations.
DATA SOURCES METHODS
A systematic literature search was conducted from existence until 11 July 2021 using Medline, Embase and ISI Web of Science databases.
STUDY ELIGIBILITY CRITERIA METHODS
Cross-sectional, prospective cohort, retrospective cohort and case-control studies that reported allo-HSCT recipients with CMV and without CMV who developed or did not develop IFIs after CMV infection.
PARTICIPANTS METHODS
Allo-HSCT recipients.
INTERVENTIONS METHODS
Not applicable.
METHODS METHODS
A systematic search, screening, data extracting and assessing study quality were independently conducted by two reviewers. The Newcastle-Ottawa scale was used to assess risk of bias. data were analysed using the pooled effect estimates of a random-effects model.
RESULTS RESULTS
A total of 18 and 12 studies were included for systematic review and meta-analysis, respectively. Post-transplant CMV infection significantly increased the risk of IFIs with a pooled hazard ratio (pHR) of 2.58 (1.78, 3.74), I
CONCLUSIONS CONCLUSIONS
Post-transplant CMV infection and high-risk CMV serostatus increased the risk of IFIs, but low-risk CMV serostatus decreased risk of IFIs among allo-HSCT recipients. Further studies are needed to identify at-risk allo-HSCT recipients as well as to focus on fungal diagnostics and prophylaxis to prevent this fungal-after-viral phenomenon.

Identifiants

pubmed: 34752926
pii: S1198-743X(21)00607-8
doi: 10.1016/j.cmi.2021.10.008
pii:
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

332-344

Informations de copyright

Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

Nipat Chuleerarux (N)

Department of Physiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Saman Nematollahi (S)

Department of Medicine, University of Arizona College of Medicine, Tucson, USA.

Achitpol Thongkam (A)

Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

M Veronica Dioverti (MV)

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA.

Kasama Manothummetha (K)

Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Pattama Torvorapanit (P)

Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Nattapong Langsiri (N)

Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Navaporn Worasilchai (N)

Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.

Rongpong Plongla (R)

Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Ariya Chindamporn (A)

Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Anawin Sanguankeo (A)

Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Nitipong Permpalung (N)

Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA. Electronic address: npermpa1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH